HHE Report No. HETA-83-019-1562, Berlex Labs., Wayne, New Jersey.
Igliewicz-R; Schmidt-M; Gann-P
NIOSH 1985 Sep:45 pages
Breathing zone samples were analyzed for quinidine (56542) at Berlex Laboratories (SIC-2834), Wayne, New Jersey in January, February, and June through August, 1983. The evaluation was requested by the local union to investigate work related skin rashes and respiratory symptoms among employees involved in producing quinidine-gluconate (7054253). Questionnaire interviews were conducted with 47 employees in April, 1984. Medical examinations including serum immunology and skin prick tests were also performed. Airborne quinidine concentrations ranged from 0.2 milligram per cubic meter (mg/m3) in the packaging area to 5.0mg/m3 in the manufacturing area. There is no federal standard for quinidine. Seventy percent of the employees reported respiratory and skin symptoms such as rashes, stuffy nose, red puffed eyes, chest tightness, and wheezing. Nineteen percent of the employees had allergic contact dermatitis. The results of the immunological and skin prick tests were negative. The authors conclude that a health hazard due to exposure to quinidine powder exists. The primary cause of the symptoms appears to be an irritant effect from exposure to the powder. Recommendations include reducing exposures with engineering controls and work practices and developing a personal air sampling protocol.
NIOSH-Author; NIOSH-Health-Hazard-Evaluation; NIOSH-Technical-Assistance-Report; Hazards-Confirmed; Chemical-processing; Region-2; Health-hazards; Respiratory-irritants; Skin-exposure; HETA-83-019-1562;
Hazard Evaluation and Technical Assistance;
NTIS Accession No.
Hazard Evaluations and Technical Assistance Branch, NIOSH, U.S. Department of Health and Human Services, Cincinnati, Ohio, Report No. HETA-83-019-1562, 45 pages, 6 references